Levodopa-induced dyskinesia (LID) in Parkinson's disease (PD) are involuntary movements caused by long-term treatment with dopaminergic replacement therapy (levodopa). During the cause of PD, most patients develop LID. In this study, the investigators plan to investigate how the cortico-basal-ganglia networks are affected in LID. The investigators will examine PD patients with and without LID as well as healthy age-matched controls using fMRI and PET. During the fMRI experiment, participants will perform a novel go-no task engaging both motor, emotional and reward brain networks. Patients will be scanned before and after intake of levodopa to study the dynamic effects of dopaminergic therapy. Furthermore, a dopamine transporter PET will be acquired to study the dopaminergic degeneration of the patients with PD.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Percent Mean Change in Blood Oxygen-level Dependent (BOLD) Scores During Modified Go/No-Go Task
Timeframe: 4 task runs of 10 minutes each
Peak force
Timeframe: 4 task runs of 10 minutes each
Reaction time
Timeframe: 4 task runs of 10 minutes each
Maximum slope
Timeframe: 4 task runs of 10 minutes each
Maximal negative slope
Timeframe: 4 task runs of 10 minutes each
Parkinson's disease severity
Timeframe: Baseline (normal medication)
Motor disease severity
Timeframe: Before and 30-60 minutes after 150 % of normal morning levodopa dose as Madopar Quick.
Non-motor disease severity
Timeframe: Baseline
Non-motor fluctuation severity
Timeframe: Baseline
Modified Hoehn and Yahr Staging
Timeframe: Baseline
Schwab and England Activities of Daily Living Scale
Timeframe: Baseline
Apathy
Timeframe: Baseline
Depression
Timeframe: Baseline
Impulsive-Compulsive Disorders (ICD)
Timeframe: Baseline
Cognitive function
Timeframe: Baseline
Impulsivity
Timeframe: Baseline
Dyskinesia severity
Timeframe: Baseline (usual medication intake) as well as before and 30-60 minutes after 150 % of normal morning levodopa dose as Madopar Quick (range 0-104), higher score = higher dyskinesia severity
Dopaminergic degeneration
Timeframe: Baseline
Age
Timeframe: Baseline
Disease duration of Parkinson's disease
Timeframe: Baseline
Duration of levodopa-induced dyskinesia
Timeframe: Baseline
Medication
Timeframe: Baseline